CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell...

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's...

Bristol Myers Squibb (BMY) closed at $49.80 in the latest trading session, marking a -0.32% move from the prior day.

LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...

Bristol Myers Squibb (BMY) closed at $49.95 in the latest trading session, marking a +0.46% move from the prior day.

Alnylam presents detailed data from the HELIOS-B study, seeking to expand Amvuttra's label to include the treatment of ATTR amyloidosis with...

The Queen Elizabeth Hospital says its Accident and Emergency Department is responding to “a significant increase” in the number of patients...

In the most recent trading session, Bristol Myers Squibb (BMY) closed at $48.59, indicating a -1.4% shift from the previous trading day.

Competitive: Bristol Myers Squibb: Working with Us Challenging. Meaningful. Life-changing. Those aren't words that are usually associated with a job....

Competitive: Bristol Myers Squibb: Working with Us Challenging. Meaningful. Life-changing. Those aren't words that are usually associated with a job....